Novartis Pipeline

Benefiting from our continued focus on innovation,Novartis has one of the industry’s most competitive pipelines。Many of these projects,which include new molecular entities as well as additional indications and different formulations for marketed products,are for medicines that could significantly advance treatment standards for patients worldwide。This table provides an overview of selected projects in development。Please note:the Novartis Pipeline data is updated quarterly。

下载Novartis Pipeline from the 2023 Annual Report(PDF0.1MB)

显示过滤器
Showing103 results
  • AAA601
    Lutathera®
    Gastroenteropancreatic neuroendocrine tumors,1st line inG2/3tumors(GEP-NET1LG3)
    Oncology:Solid Tumors Phase3 2024 Radioligand therapy target SSTR
    Supplementary Indication
  • AAA601
    Lutathera®
    GEPNET,pediatrics
    Oncology:Solid Tumors Phase2 Radioligand therapy target SSTR
  • AAA601
    Lutathera®
    Glioblastoma
    Oncology:Solid Tumors Phase2 Radioligand therapy target SSTR
  • AAA601
    Lutathera®
    1L ES-SCCL
    Oncology:Solid Tumors Phase2 Radioligand therapy target SSTR
  • AAA603
    177Lu-NeoB
    断路器,断路器
    Oncology:Solid Tumors Phase1 Radioligand therapy target GRP R
  • AAA603
    177Lu-NeoB
    Glioblastoma multiforme
    Oncology:Solid Tumors Phase1 Radioligand therapy target GRP R
  • AAA603
    177Lu-NeoB
    多级solid tumors
    Oncology:Solid Tumors Phase1 ≥2027 Radioligand therapy target GRP R
    Lead Indication
  • AAA604
    AAA604
    Pancreatic cancer
    Oncology:Solid Tumors Phase1 Radioligand therapy target integrin beta-3/beta-5
  • AAA614
    AAA614
    固体tumors
    Oncology:Solid Tumors Phase1 Radioligand therapy target FAP
    Lead Indication
  • AAA617
    Pluvicto®
    Metastatic hormone sensitive prostate cancer(mHSPC)
    Oncology:Solid Tumors Phase3 2025 Radioligand therapy target PSMA
    新建指示
  • AAA617
    Pluvicto®
    Oligometatic prostate cancer
    Oncology:Solid Tumors Phase3 ≥2027
  • AAA617
    Pluvicto®
    Metastatic castration-resistant prostate cancer(mCRPC)pre-taxane
    Oncology:Solid Tumors Phase3 2024 Radioligand therapy target PSMA
    新建指示
  • AAA 802
    225Ac-PSMA-R2
    Prostate cancer
    Oncology:Solid Tumors Phase1 Radioligand therapy target PSMA
  • AAA817
    225Ac-PSMA-617
    元数据分析程序
    Oncology:Solid Tumors Phase1 Radioligand therapy target PSMA
    Lead Indication
  • ABL001
    Scemblix®
    Chronic myeloid leukemia,1st line
    Oncology:Hematology Phase3 2024 BCR-ABL inhibitor
    新建指示
  • ABL001
    Scemblix®
    Chronic myeloid leukemia,2L,pediatrics
    Oncology:Hematology Phase2 2026 BCR-ABL inhibitor
    新建指示
  • AIN457
    Cosentyx®
    回转器cuff tendinopathy
    Immunology Phase3 IL17A inhibitor(Anti-interleukin-17monoclonal antibody)
  • AIN457
    Cosentyx®
    Giant cell arteritis(GCA)
    Immunology Phase3 2025 IL17A inhibitor(Anti-interleukin-17monoclonal antibody)
    Supplementary Indication
  • AIN457
    Cosentyx®
    多边形磁辐射
    Immunology Phase3 2026 IL17A inhibitor(Anti-interleukin-17monoclonal antibody)
  • AMG334
    Aimovig®
    Migraine,pediatrics
    In-market Brands and Global Health Phase3 ≥2027 Selective CGRP receptor antagonist
    Supplementary Indication
Legend

组合abbreviations:
fulv fulvestrant
tmx tamoxifen
gsn goserelin
NSAI Non-steroidal aromatase inhibitor
Taf Tafinlar®(dabrafenib)
中间,中间®(trametinib)

a EU filing,approved in US。
b US filing,approved in EU。
c US filing,submitted in EU。
d US pending submission,approved in EU
e EU filing,submitted in US。

Disclaimer

This information was factually accurate on the date it was published。Novartis assumes no duty to update the information to reflect subsequent developments。Readers should not rely upon the information on this page as current or accurate after its publication date。For the latest information on the Novartis'pipeline,readers should visit the News and Investors sections of our website。This information constitutes forward-looking statements relating to Novartis AG's business,including express or implied discussions regarding potential new products,potential new indications for existing products,orregarding potential future revenues from any such products。Such forward-looking statements reflect the current views of Novartis AG regarding future events,and involve known and unknown risks,uncertainties and other factors that may cause actual results to be materially different from any future results,performance or achievements expressed or implied suments by。There can be no guarantee that any new products will be approved for sale in any market,or that any new indications will be approved for existing products in any market,or that such products will achieve any particular revenue levels。

在particular,management's expectations could be affected by,among other things,uncertainties involved in the development of new pharmaceutical products;unexpected clinical trial results,including additional analysis of existing clinical data or unexpected new clinical data;unexpected regulatory actions or delays or government regulation generally;Novartis Group’s ability to obtain or maintain patent or other proprietary intellectual property保护,including the uncertainties involved in the USlitigation process;competition in general;government,industry,and general public pricing and other political pressures;and other risks and factors referred to in Novartis AG's current Form20-F on file with the US Securities and Exchange Commission。Should one or more of these risks or uncertainties materialize,or should underlying assumptions prove incorrect,actual results may vary materially from those described herein as anticipated,believed,estimated or expected。